{"disease":{"id":"b-cell-non-hodgkin-lymphoma","name":"b cell non hodgkin lymphoma"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"fludarabine-phosphate","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"ruxience","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":60,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":70,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"fludarabin","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02847130","title":"Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03888105","title":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03671018","title":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":422,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06564038","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":408,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04748185","title":"Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":358,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06230224","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05991388","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT04970901","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":false},{"nct_id":"NCT06725524","title":"A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT07081022","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT01000753","title":"Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06052826","title":"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":164,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05164770","title":"Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT03417414","title":"Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT07439653","title":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":155,"lead_sponsor_name":"TORL Biotherapeutics, LLC","has_results":false},{"nct_id":"NCT05805943","title":"Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05395533","title":"A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":147,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT03571568","title":"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT05097443","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT06561425","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Galapagos NV","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05091541","title":"A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Nanjing IASO Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05260203","title":"MargheRITA (Remote Intelligence for Therapeutic Adherence)","phase":"NA","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Advice Pharma Group srl","has_results":false},{"nct_id":"NCT06238648","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT03677141","title":"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07432022","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":115,"lead_sponsor_name":"Shanghai EpimAb Biotherapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT01351935","title":"Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT06251180","title":"Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Guangzhou Lupeng Pharmaceutical Company LTD.","has_results":false},{"nct_id":"NCT06386315","title":"Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05618327","title":"Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT02044276","title":"A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":false},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02564744","title":"Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Debiopharm International SA","has_results":true},{"nct_id":"NCT06189391","title":"A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"MSD R&D (China) Co., Ltd.","has_results":false},{"nct_id":"NCT06806033","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05436223","title":"Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hrain Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06392477","title":"A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT05840289","title":"A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":94,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT05685173","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07123454","title":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04746131","title":"Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":90,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT05190068","title":"HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT07168980","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Children's Cancer Group, China","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}